Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9629 posts found.

novartis_outside_1

Novartis’ Ilaris gets US FDA breakthrough therapy designation to treat fever syndromes

April 27, 2016 Business Services, Research and Development Breakthrough Therapy Designation, Novartis, US FDA, periodic fever syndromes

Novartis (VTX: NOVN) on Wednesday said its drug to treat three rare types of periodic fever syndromes has been granted …
News
hawthorn_eisai

Eisai poaches senior Pfizer and Sanofi execs for neurology group

April 26, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim

Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …
Appointment
george-freeman1

Northern Powerhouse life sciences contributing £10 billion to UK economy, says minister

April 26, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Jobs, Northern Powerhouse, contribution, economy, exporting, george freeman, investment, life sciences, minister, north

Minister for Life Sciences, George Freeman MP, has revealed that life sciences businesses within the Northern Powerhouse are contributing over …
News
clinicaltrial1

US panel says Sarepta’s trial DMD drug not proven effective

April 26, 2016 Manufacturing and Production, Research and Development DMD, US FDA, drug trial, sarepta

A US advisory committee has concluded Sarepta Therapeutics’ (Nasdaq: SRPT) trial drug to treat muscle wasting condition has not proved …
News
credit_bayerag

Bayer’s earnings beat estimates as blockbusters shine

April 26, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales

Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …
News
astrazeneca_building_white

AstraZeneca’s COPD therapy gets US FDA approval

April 26, 2016 Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval

UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …
News
gilead-sciences

EU grants approval for Gilead’s HIV treatment Descovy

April 26, 2016 Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf

Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …
News
joseph_papa

Valeant names Joseph Papa as new chief executive officer

April 25, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Chairman, Valeant, joseph papa, new, new ceo, papa, pearson

Valeant Pharmaceuticals has announced that Joseph C. Papa will succeed Michael Pearson as chairman and chief executive officer of the …
Appointment
test_results

FDA, WHO criticise integrity of data at contract research firm Semler

April 25, 2016 Research and Development, Sales and Marketing FDA, India, WHO, World Health Organisation, semler, semler research

The US Food and Drug Administration and the World Health Organisation have raised serious concerns related to violations of good …
News
stocks1

Weekly Movers: PTC Therapeutics, Celator Pharmaceuticals, Chiasma, Sarepta and more…

April 25, 2016 Research and Development, Sales and Marketing

With the earnings season in full swing this week investors focussed on the impact on stock moves as companies declared …
Feature

Pfizer, GSK’s anti-smoking drugs not linked to increase in serious neuropsychiatric adverse events – Study

April 25, 2016 Research and Development, Sales and Marketing

Pharma giant Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline) did not show an increase in serious neuropsychiatric adverse events …
News
sample

Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016 Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …
News
trials

AbbVie announces further industry and academic collaborations

April 22, 2016 Medical Communications, Research and Development AbbVie, collaboration, commercialisation, cytomx, partnership, research, university of chicago

AbbVie (NYSE: ABBV) has announced further collaborations that will see it partner with industry and academia to develop oncology candidates …
News
lab

Novartis muscular drug fails in Phase III trials

April 22, 2016 Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
News
blue_jeans

Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease

April 21, 2016 Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease

Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
News
The Gateway to Local Adoption Series

Latest content

Sandoz opens biosimilar development centre in Slovenia

June 19, 2026

Codis announces three senior business development appointments

June 18, 2026

US laboratory approval supports launch of lung cancer blood test

June 17, 2026

Study to examine ways of improving diabetes care for younger adults

June 16, 2026

Phase 2 endometriosis trial reaches recruitment milestone

June 15, 2026